Produção Nacional
Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity
2017; Baishideng Publishing Group; Volume: 8; Issue: 1 Linguagem: Inglês
10.4292/wjgpt.v8.i1.26
ISSN2150-5349
AutoresDiogo Telles‐Correia, António Barbosa, Helena Cortez‐Pinto, Carlos Campos, Nuno B F Rocha, Sérgio Machado,
Tópico(s)Poisoning and overdose treatments
ResumoThe liver is the organ by which the majority of sub stances are metabolized, including psychotropic drugs.There are several pharmacokinetic changes in endstage liver disease that can interfere with the metabolization of psychotropic drugs.This fact is particularly true in drugs with extensive firstpass metabolism, highly protein bound drugs and drugs depending on phase I hepatic metabolic reactions.Psychopharmacological agents are also associated with a risk of hepatotoxicity.The evidence is insufficient for definite conclusions regarding the prevalence and severity of psychiatric druginduced liver injury.Highrisk psychotropics are not advised when there is preexisting liver disease, and after starting a psychotropic agent in a patient with hepatic impairment, frequent liver function/lesion monitoring is advised.The authors carefully review the pharmacokinetic disturbances induced by endstage liver disease and the potential of psychopharmacological agents for liver toxicity.
Referência(s)